Publications

2024

A general system for targeting MHC class II–antigen complex via a single adaptable loop.

Du H, Liu J, Jude KM, Yang X, Li Y, Bell B, Yang H, Kassardjian A, Blackson W, Mobedi A, Parekh U, Sperberg A, Julien JP, Mellins E, Garcia KC, Huang P.

Nature Biotechnology. 2024 December 13. doi: 10.1038/s41587-024-02466-y.

bioRxiv. 2024 Jan 30. doi: 10.1101/2024.01.26.577489.

Human ITGAV variants are associated with immune dysregulation, brain abnormalities, and colitis.

Ghasempour S, Warner N, Guan R, Rodari MM, Ivanochko D, Whittaker Hawkins R, Marwaha A, Nowak JK, Liang Y, Mulder DJ, Stallard L, Li M, Yu DD, Pluthero FG, Batura V, Zhao M, Siddiqui I, Upton JEM, Hulst JM, Kahr WHA, Mendoza-Londono R, Charbit-Henrion F, Hoefsloot LH, Khiat A, Moreira D, Trindade E, do Céu Espinheira M, Pinto Pais I, Weerts MJA, Douben H, Kotlarz D, Snapper SB, Klein C, Dowling JJ., Julien JP, Joosten M, Cerf-Bensussan N, Freeman SA, Parlato M, van Ham TJ, Muise AM.

Journal of Experimental Medicine. 2024 November 11; 221(12): e20240546. doi: 10.1084/jem.20240546.

A human-serum-free medium can induce more infectious P. falciparum gametocytes than a conventional human-serum-containing medium.

Miura K, Deng B, Suresh RV, Gebremicale YT, Zhou L, Pham TP, Roche K, Diouf A, Lovell JF, Julien JP, Long CA.

Scientific Reports. 2024 September 27; 14, 22052. doi: 10.1038/s41598-024-73843-5.

A comparative immunological assessment of multiple clinical-stage adjuvants for the R21 malaria vaccine in nonhuman primates.

Arunachalam PS, Ha NY, Dennison SM, Spreng RL, Seaton KE, Xiao P, Feng Y, Zarnitsyna VI, Kazmin D, Hu M, Santagata JM, Xie X, Rogers K, Shirreff LM, Chottin C, Spencer AJ, Dutta S, Prieto K, Julien JP, Tomai M, Fox CB, Villinger F, Hill AVS, Tomaras GD, Pulendran B.

Science Translational Medicine. 2024 July 31; 16(758), adn6605. doi: 10.1126/scitranslmed.adn6605.

Humanization of pan-HLA-DR mAb 44H10 Hinges on Critical Residues in the Antibody Framework.

Kassardjian A, Ivanochko D, Barber B, Jetha A, Julien JP.

Antibodies. 2024 July 16; 13(3), 57. doi: 10.3390/antib13030057.

Target-agnostic identification of human antibodies to Plasmodium falciparum sexual forms reveals cross stage recognition of glutamate-rich repeats.

Amen A, Yoo R, Fabra-Garcia A, Bolscher J, Stone WJR, Bally I, Dergan-Dylon S, Kucharska I, de Jong RM, de Bruijni M, Bousema T, King CR, MacGill RS, Sauerwein RW, Julien JP, Poignard P, Jore MM.

eLife. 2024 May 23. doi: 10.7554/eLife.97865.1.

bioRxiv. 2023 Nov 5. doi: 10.1101/2023.11.03.565335.

Disproportionate Rates of COVID-19 Among Black Canadian Communities: Lessons from a Cross-Sectional Study in the First Year of the Pandemic.

Allen UA, Barton M, Upton J, Bailey A, Campigotto A, Abdulnoor M, Julien JP, Gubbay J, Kissoon N, Litosh A, La Neve MR, Wong P, Allen A, Bailey R, Byrne W, Jagoowani R, Phillips C, Merreles Pulcini M, Polack A, Prescod C, Siddiqi A, Summers A, Thompson K, Thompson S, James C, for the seroMARK Research Group.

Journal of Racial and Ethnic Health Disparities. 2024 Jan 22. ofad500.1652. doi: 10.1007/s40615-023-01903-z.

2023

Structural elucidation of full-length Pfs48/45 in complex with potent mAbs isolated from a naturally exposed individual.

Kucharska I, Ivanochko D, Hailemariam S, Inklaar MR, Kim HR, Teelen K, Stoter R, van de Vegte-Bolmer M, van Gemert GJ, Semesi A, McLeod B, Ki A, Lee WK, Rubinstein JL, Jore MM, Julien JP.

Research Square. 2023 Nov 30. doi: 10.21203/rs.3.rs-3605634.

Molecular determinants of cross-reactivity and potency by VH3-33 antibodies against the Plasmodium falciparum circumsporozoite protein.

Thai E, Murugan R, Binter S, Burn Aschner C, Prieto K, Kassardjian A, Obraztsova AS, Kang RW, Flores-Garcia Y, Mathis-Torres S, Li K, Horn GQ, Huntwork RHC, Bolscher JM, de Bruijni MHC, Sauerwein R, Dennison SM, Tomaras GD, Zavala F, Kellam P, Wardemann H, Julien JP.

Cell Reports. 2023 Oct 28; 42(11), 113330. doi: 10.1016/j.celrep.2023.113330.

A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo.

Burn Aschner C, Muthuraman K, Kucharska I, Cui H, Prieto K, Nair MS, Wang M, Huang Y, Christie-Holmes N, Poon B, Lam J, Sultana A, Kozak R, Mubareka S, Rubinstein JL, Rujas E, Treanor B, Ho DD, Jetha A, Julien JP.

Sci Transl Med. 2023 May 24; 15(697): eadf45. doi: 10.1126/scitranslmed.adf4549.

bioRxiv. 2022 Oct 24. doi: 10.1101/2022.10.23.513379.

Modular adjuvant-free pan-HLA-DR-immunotargeting subunit vaccine against SARS-CoV-2 elicits broad sarbecovirus-neutralizing antibody responses.

Kassardjian A, Sun E, Sookhoo J, Muthuraman K, Frias Boligan K, Kucharska I, Rujas E, Jetha A, Branch DR, Babiuk S, Barber B, Julien JP.

Cell Rep. 2023 Apr 25; 42(4): 112391. doi: 10.1016/j.celrep.2023.112391.

Molecular and functional properties of human Plasmodium falciparum CSP C-terminus antibodies.

Oludada OE, Costa G, Burn Aschner C, Obraztsova AS, Prieto K, Canetta C, Hoffman SL, Kremsner PG, Mordmüller B, Murugan R, Julien JP, Levashina EA, Wardemann H.

EMBO Mol Med. 2023 Apr 21; e17454. doi: 10.15252/emmm.202317454

bioRxiv. 2023 Jan 19. doi: 10.1101/2023.01.19.524692.

Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model.

Ludwig J, Scally SW, Costa G, Hoffmann S, Murugan R, Lossin J, Prieto K, Obraztcova A, Lobeto N, Franke-Fayard B, Janse CJ, Lebas C, Collin N, Binter S, Kellam P, Levashina EA, Wardemann H, Julien JP.

npj Vaccines. 2023 Apr 7; 8: 52. doi: 10.1038/s41541-023-00653-7.

Therapeutic targeting of LIF overcomes macrophage mediated immunosuppression of the local tumor microenvironment.

Hallett RM, Bonfill-Teixidor E, Iurlaro R, Arias A, Neva-Alejo A, Raman S, Bayliss P, Egorova O, McGray AJR, Lau E, Bosch A, Beilschmidt M, Choudhry A, Maetzel D, Fransson J, Huber-Ruano I, Anido J, Julien JP, Giblin P, Seoane J.

Clin Cancer Res. 2023 Feb 16; 29(4): 791-804. doi: 10.1158/1078-0432.CCR-21-1888.

Identification of highly potent transmission-blocking human monoclonal antibodies to Plasmodium falciparum Pfs230 in naturally exposed individuals.

Ivanochko D, Fabra-García A, Teelen K, van de Vegte-Bolmer M, van Gemert GJ, Newton J, Semesi A, de Bruijni M, Bolscher J, Ramjith J, Szabat M, Vogt S, Kraft L, Duncan S, Lee SM, Kamya MR, Feeney ME, Jagannathan P, Greenhouse B, Sauerwein RW, King CR, MacGill RS, Bousema T, Jore MM, Julien JP.

Immunity. 2023 Feb 14; 56(2): 420-432.e7. doi:10.1016/j.immuni.2023.01.013.

SSRN (Sneak Peek). 2022 Sep 8.

Highly potent naturally acquired human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to mosquitoes.

Fabra-Garcia A, Hailemariam S, de Jong RM, Janssen K, Teelen K, van de Vegte-Bolmer M, van Gemert GJ, Ivanochko D, Semesi A, McLeod B, Vos MW, de Bruijni MHC, Bolscher JM, Szabat M, Vogt S, Kraft L, Duncan S, Kamya MR, Feeney ME, Jagannathan P, Greenhouse B, Sauerwein RW, King CR, MacGill RS, BousemaT, Julien JP, Jore MM.

Immunity. 2023 Feb 14; 56(2): 406-419.e7. doi:10.1016/j.immuni.2023.01.009.

SSRN (Sneak Peek). 2022 Sep 7.

2022

High-density binding to Plasmodium falciparum circumsporozoite protein repeats by inhibitory antibody elicited in mouse with human immunoglobulin repertoire.

Kucharska I, Binter S, Murugan R, Scally SW, Ludwig J, Prieto K, Thai E, Costa G, Li K, Horn GQ, Flores-Garcia Y, Bosch A, Sicard T, Rubinstein JL, Zavala F, Dennison SM, Tomaras GD, Levashina EA, Kellam P, Wardemann H, Julien JP.

PLOS Pathog. 2022 Nov 28. doi: 10.1371/journal.ppat.1010999.

Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses.

McLeod B, Mabrouk MT, Miura K, Ravichandran R, Kephart S, Hailemariam S, Pham TP, Semesi A, Kucharska I, Kundu P, Huang WC, Johnson M, Blackstone A, Pettie D, Murphy M, Kraft JC, Leaf EM, Jiao Y, van de Vegte-Bolmer M, van Gemert GJ, Ramjith J, King CR, MacGill RS, Wu Y, Lee KK, Jore MM, King NP, Lovell JF, Julien JP.

Immunity. 2022 Sep 13; 55, 1-13. doi:10.1016/j.immuni.2022.07.015.

Dual inhibition of vacuolar ATPase and TMPRSS2 is required for complete blockade of SARS-CoV-2 entry into cells.

Icho S, Rujas E, Muthuraman K, Tam J, Liang H, Harms S, Liao M, Falzarano D, Julien JP, Melnyk R.

Antimicrob Agents Chemother. 2022 Jul 19; 66(7):e0043922. doi: 10.1128/aac.00439-22.

bioRxiv. 2022 Mar 14. doi: 10.1101/2022.03.11.484006.

Engineering pan–HIV-1 neutralization potency through multispecific antibody avidity.

Rujas E, Cui H, Burnie J, Aschner CB, Zhao T, Insausti S, Muthuraman K, Semesi A, Ophel J, Nieva JL, Seaman MS, Guzzo C, Treanor B, Julien JP.

Proc. Natl. Acad. Sci. U.S.A. 2022 Jan 21; 119(4):e2112887119. doi:10.1073/pnas.2112887119.

Structural basis of Plasmodium vivax inhibition by antibodies binding to the circumsporozoite protein repeats.

Kucharska I, Hossain L, Ivanochko D, Yang Q, Rubinstein JL, Pomès R, Julien JP.

eLife. 2022 Jan 13; 11:e72908. doi:10.7554/eLife.72908.

bioRxiv. 2021 Sep 1. doi: 10.1101/2021.08.31.458469.

GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.

Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, Dhingra S, Sotillo E, Buongervino S, Pascual-Pasto G, Garrigan E, Xu P, Huang J, Salzer B, Delaidelli A, Raman S, Cui H, Martinez B, Bornheimer SJ, Sahaf B, Alag A, Fetahu IS, Hasselblatt M, Parker KR, Anbunathan H, Hwang J, Huang M, Sakamoto K, Lacayo NJ, Klysz DD, Theruvath J, Vilches-Moure JG, Satpathy AT, Chang HY, Lehner M, Taschner-Mandl S, Julien JP, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL.

Cancer Cell. 2022 Jan 10; 40(1):53-69.e9. doi: 10.1016/j.ccell.2021.12.005.

2021

Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease.

Sugiyama MG, Cui H, Redka DS, Karimzadeh M, Rujas E, Maan H, Hayat S, Cheung K, Misra R, McPhee JB, Viirre RD, Haller A, Botelho RJ, Karshafian R, Sabatinos SA, Fairn GD, Madani Tonekaboni SA, Windemuth A, Julien JP, Shahani V, MacKinnon SS, Wang B, Antonescu CN.

Sci Rep. 2021 Dec 2; 11, 1, 23315. doi: 10.1038/s41598-021-02432-7.

bioRxiv. 2021 Apr 13. doi: 10.1101/2021.04.13.439274.

Lyophilized, thermostable Spike or RBD immunogenic liposomes induce protective immunity against SARS-CoV-2 in mice.

Mabrouk MT, Chiem K, Rujas E, Huang WC, Jahagirdar D, Quinn B, Surendran Nair M, Nissly RH, Cavener VS, Boyle NR, Sornberger TA, Kuchipudi SV, Ortega J, Julien JP, Martinez-Sobrido L, Lovell J.

Sci Adv. 2021 Dec 1; 7, 49. doi: 10.1126/sciadv.abj1476.

Systematic engineering of optimized autonomous heavy-chain variable domains.

Nilvebrant J, Ereño-Orbea J, Gorelik M, Julian MC, Tessier PM, Julien JP, Sidhu SS.

J Mol Biol. 2021 Sep 9; 167241. doi: 10.1016/j.jmb.2021.167241.

Focal accumulation of aromaticity at the CDRH3 loop mitigates 4E10 polyreactivity without altering its HIV neutralization profile.

Rujas E, Leaman DP, Insausti S, Carravilla P, García-Porras M, Largo E, Morillo I, Sánchez-Eugenia R, Zhang L, Cui H, Iloro I, Elortza F, Julien JP, Eggeling C, Zwick MB, Caaveiro JMM, Nieva JL.

iScience. 2021 Aug 17; 102987. doi: 10.1016/j.isci.2021.102987.

A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope.

Raman S, Buongervino SN, Lane M, Zhelev DV, Zhu Z, Cui H, Martinez B, Martinez D, Wang Y, Upton K, Patel K, Rathi KS, Navia CT, Harmon DB, Pawel B, Dimitrov DS, Maris JM, Julien JP, Bosse KR.

Cell Rep Med. 2021 Jul 20; 2, 7, 100344. doi: 10.1016/j.xcrm.2021.100344.

Sneak Peak. 2020 Sep 18.

Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22.

Ereño-Orbea J, Liu X, Sicard T, Kucharska I, Li W, Borovsky D, Cui H, Feng Y, Dimitrov DS, Julien JP.

J Biol Chem. 2021 Jul 14; 100966. doi: 10.1016/j.jbc.2021.100966.

Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers.

Rujas E, Kucharska I, Tan YZ, Benlekbir S, Cui H, Zhao T, Wasney GA, Budylowski P, Guvenc F, Newton JC, Sicard T, Semesi A, Muthuraman K, Nouanesengsy A, Aschner CB, Prieto K, Bueler SA, Youssef S, Liao-Chan S, Glanville J, Christie-Holmes N, Mubareka S, Gray-Owen SD, Rubinstein JL, Treanor B, Julien JP.

Nat Commun. 2021 Jun 16; 12:3661. doi: 10.1038/s41467-021-23825.

bioRxiv. 2020 Oct 16. doi: 10.1101/2020.10.15.341636.

Video highlight of manuscript:

Polymeric assembly of endogenous Tuberous Sclerosis Protein Complex.

Dai DL, Hasan SNM, Woollard G, Bueler SA, Julien JP, Rubinstein JL, Mazhab-Jafari MT.

Biochemistry. 2021 Jun 3; 60, 23, 1808–1821. doi: 10.1021/acs.biochem.1c00269.

bioRxiv. 2021 Jan 19. doi: 10.1101/2021.01.18.426261.

2020

Structural ordering of the Plasmodium berghei circumsporozoite protein repeats by inhibitory antibody 3D11.

Kucharska I, Thai E, Srivastava A, Rubinstein JL, Pomès R, Julien JP.

eLife. 2020 Nov 30; 9:e59018. doi:10.7554/eLife.59018.

bioRxiv. 2020 Jun 4. doi:10.1101/2020.06.02.131110.

B cell targeting by molecular adjuvants for enhanced immunogenicity.

Sicard T, Kassardjian A, Julien JP.

Expert Rev Vaccines. 2020 Nov 30. doi: 10.1080/14760584.2020.1857736.

Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.

Rujas E, Cui H, Sicard T, Semesi A, Julien JP.

Nat Commun. 2020 Oct 8; 11:5066. doi: 10.1038/s41467-020-18828-4.

A Versatile Soluble Siglec Scaffold for Sensitive and Quantitative Detection of Glycan Ligands.

Rodrigues E, Jung J, Park H, Loo C, Soukhtehzari S, Kitova EN, Mozaneh F, Daskhan G, Aghanya V, Sarkar S, Streith L, St. Laurent C, Julien JP, West LJ, Williams KC, Klassen JS, Macauley MS.

Nat Commun. 2020 Oct 8; 11:5091. doi: 10.1038/s41467-020-18907-6.

bioRxiv. 2020 Jul 29. doi: 10.1101/2020.07.28.223164.

Affinity for the Interface Underpins Potency of Antibodies Operating In Membrane Environments.

Rujas E, Insausti S, Leaman DP, Carravilla P, González-Resines S, Monceaux V, Sánchez-Eugenia R, García-Porras M, Iloro I, Zhang L, Elortza F, Julien JP, Saéz-Cirión A, Zwick MB, Eggeling C, Ojida A, Domene C, Caaveiro JMM, Nieva JL.

Cell Rep. 2020 Aug 18; 32 (7): 108037. doi: 10.1016/j.celrep.2020.108037.

A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity.

Thai E , Costa G, Weyrich A, Murugan R, Oyen D, Flores-Garcia Y, Prieto K, Bosch A, Valleriani A, Wu NC, Pholcharee T, Scally SW, Wilson IA, Wardemann H, Julien JP, Levashina EA.

J Exp Med. 2020 Aug 13; 217 (11): e20200061. doi: 10.1084/jem.20200061.

bioRxiv. 2020 Jan 14. doi: 10.1101/2020.01.13.904425.

Recognition of Semaphorin Proteins by P. sordellii Lethal Toxin Reveals Principles of Receptor Specificity in Clostridial Toxins.

Lee H, Beilhartz GL, Kucharska I, Raman S, Cui H, Lam M, Rubinstein JL, Schramek D, Julien JP, Melnyk RA, Taipale M.

Cell. 2020 Jul 23; 182 (2): 345–356.e16. doi: 10.1016/j.cell.2020.06.005.

bioRxiv. 2019 Dec 10. doi: 10.1101/871707.

Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs.

Murugan R, Scally SW, Costa G, Mustafa G, Thai E, Decker T, Bosch A, Prieto K, Levashina EA, Julien JP, Wardemann H.

Nat Med. 2020 May 25; 26 (7):1135-1145. doi: 10.1038/s41591-020-0881-9.

bioRxiv. 2019 Oct 9. doi: 10.1101/798769.

De novo protein design enables the precise induction of RSV-neutralizing antibodies.

Sesterhenn F, Yang C, Bonet J, Cramer JT, Wen X, Wang Y, Chiang CI, Abriata LA, Kucharska I, Castoro G, Vollers SS, Galloux M, Dheilly E, Rosset S, Corthésy P, Georgeon S, Villard M, Richard CA, Descamps D, Delgado T, Oricchio E, Rameix-Welti MA, Más V, Ervin S, Eléouët JF, Riffault S, Bates JT, Julien JP, Li Y, Jardetzky T, Krey T, Correia BE.

Science. 2020 May 15; 368 (6492): eaay5051. doi: 10.1126/science.aay5051.

2019

Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25.

McLeod B, Miura K, Scally SW, Bosch A, Nguyen N, Shin H, Kim D, Volkmuth W, Rämisch S, Chichester JA, Streatfield S, Woods C, Schief WR, Emerling D, King CR, Julien JP.

Nat Commun. 2019 Sep 24; 10: 4328. doi: 10.1038/s41467-019-11980-6.

Antibodies against Plasmodium falciparum malaria at the molecular level.

Julien JP, Wardemann H.

Nat Rev Immunol. 2019 Aug 28; 19: 761-775. doi: 10.1038/ s41577-019-0209-5.

Cholesterol Interaction Directly Enhances Intrinsic Activity of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).

Chin S, Ramjeesingh M, Hung M, Ereño-Oreba J, Cui H, Laselva O, Julien JP, Bear CE.

Cells. 2019 Jul 31;8(8). pii: E804. doi: 10.3390/cells8080804.

bioRxiv. 2018 Dec 16. doi: 10.1101/495010.

N-linked glycosylation regulates CD22 organization and function.

Wasim L, Buhari FH, Yoganathan M, Sicard T, Ereno-Orbea J, Julien JP, Treanor B.

Front. Immunol. 2019 Mar 14; 10: 699. doi: 10.3389/fimmu.2019.00699.

Structure-guided design fine-tunes pharmacokinetics, tolerability, and antitumor profile of multispecific frizzled antibodies.

Raman S, Beilschmidt M, To M, Lin K, Lui F, Jmeian Y, Ng M, Fernandez M, Fu Y, Mascall K, Duque A, Wang X, Pan G, Angers S, Moffat J, Sidhu SS, Magram J, Sinclair AM, Fransson J, Julien JP.

Proc. Natl. Acad. Sci. U.S.A. 2019 Mar 20; 116(14): 6812-6817. doi: 10.1073/pnas.1817246116.

Molecular recognition of the native HIV-1 MPER revealed by STED microscopy of single virions.

Carravilla P, Chojnacki J, Rujas E, Insausti S, Largo E, Waithe D, Apellaniz B, Sicard T, Julien JP, Eggeling C, Nieva JL.

Nat Commun. 2019 Jan 8; 10: 78. doi: 10.1038/s41467-018-07962-9.

2018

Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45.

Kundu P, Semesi A, Jore MM, Morin MJ, Price VL, Liang A, Li J, Miura K, Sauerwein RW, King CR, Julien JP.

Nat Commun. 2018 Oct 26; 9: 4458. doi: 10.1038/s41467-018-06742-9.

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques.

Ereño-Orbea J, Sicard T, Cui H, Akula I, Julien JP.

J Vis Exp. 2018 Jul 5; 137: e57750. doi: 10.3791/57750.

Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope.

Imkeller K, Scally SW, Bosch A, Martí GP, Costa G, Triller G, Murugan R, Renna V, Jumaa H, Kremsner PG, Sim BKL, Hoffman SL, Mordmüller B, Levashina E, Julien JP, Wardemann H.

Science. 2018 Jun 22; 360(6395): 1358-1362. doi: 10.1126/science.aar5304. First Release 2018 Jun 7.

Video highlight of manuscript:

Peek-Peak-Pique: Repeating Motifs of Subtle Variance Are Targets for Potent Malaria Antibodies.

Scally SW, Julien JP.

Immunity. 2018 May 15; 48(5): 851–854. doi: 10.1016/j.immuni.2018.04.037.

Molecular basis of unusually high neutralization resistance in tier 3 HIV-1 strain 253-11.

Moyo T, Ereño-Orbea J, Jacob RA, Pavillet CE, Kariuki SM, Tangie EN, Julien JP, Dorfman JR.

J Virol. 2018 Jun 29; 92(14). pii: e02261-17. doi: 10.1128/JVI.02261-17.

Structural basis of enhanced crystallizability induced by a molecular chaperone for antibody antigen-binding fragments.

Ereño-Orbea J, Sicard T, Cui H, Carson J, Hermans P, Julien JP.

J Mol Biol. 2018 Feb 2; 430(3): 322–336. doi: 10.1016/j.jmb.2017.12.010.

Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection.

Scally SW, Murugan R, Bosch A, Triller G, Costa G, Mordmüller B, Kremsner PG, Sim BKL, Hoffman SL, Levashina EA, Wardemann H, Julien JP.

J Exp Med. 2018 Jan 2; 215(1): 63–75. doi: 10.1084/jem.20170869.

2017

Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies.

Triller G, Scally SW, Costa G, Pissarev M, Kreschel C, Bosch A, Marois E, Sack BK, Murugan R, Salman AM, Janse CJ, Khan SM, Kappe SHI, Adegnika AA, Mordmüller B, Levashina EA, Julien JP, Wardemann H.

Immunity. 2017 Dec 19; 47(6):1197-1209.e10. doi: 10.1016/j.immuni.2017.11.007.

Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25.

Scally SW, McLeod B, Bosch A, Miura K, Liang Q, Carroll S, Reponen S, Nguyen N, Giladi E, Rämisch S, Yusibov V, Bradley A, Lemiale F, Schief WR, Emerling D, Kellam P, King CR, Julien JP.

Nat Commun. 2017 Nov 16; 8:1568. doi: 10.1038/s41467-017-01924-3.

Molecular basis of human CD22 function and therapeutic targeting.

Ereño-Orbea J, Sicard T, Cui H, Mazhab-Jafari MT, Benlekbir S, Guarné A, Rubinstein JL, Julien JP.

Nat Commun. 2017 Oct 2; 8:764. doi: 10.1038/s41467-017-00836-6.

Video highlight of manuscript:

Functional defects in Clostridium difficile TcdB toxin uptake identify CSPG4 receptor binding determinants.

Gupta P, Zhang Z, Sugiman-Marangos SN, Tam J, Raman S, Julien JP, Kroh HK, Lacy DB, Murgolo N, Bekkari K, Therien AG, Hernandez LD, Melnyk RA.

J Biol Chem. 2017 Oct 20; 292(42):17290-17301. doi: 10.1074/jbc.M117.806687.

Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization.

Torrents de la Peña A, Julien JP, de Taeye SW, Garces F, Guttman M, Ozorowski G, Pritchard LK, Behrens AJ, Go EP, Burger JA, Schermer EE, Sliepen K, Ketas TJ, Pugach P, Yasmeen A, Cottrell CA, Torres JL, Vavourakis CD, van Gils MJ, LaBranche C, Montefiori DC, Desaire H, Crispin M, Klasse PJ, Lee KK, Moore JP, Ward AB, Wilson IA, Sanders RW.

Cell Rep. 2017 Aug 22; 20(8):1805-1817. doi: 10.1016/j.celrep.2017.07.077.

A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure.

Lee JH, Andrabi R, Su CY, Yasmeen A, Julien JP, Kong L, Wu NC, McBride R, Sok D, Pauthner M, Cottrell CA, Nieusma T, Blattner C, Paulson JC, Klasse PJ, Wilson IA, Burton DR, Ward AB.

Immunity. 2017 Apr 18; 46(4):690-702. doi: 10.1016/j.immuni.2017.03.017. PMID: 28423342

Key Residues at Third CDR3β Position Impact Structure and Antigen Recognition of Human Invariant NK TCRs.

Chamoto K, Guo T, Scally SW, Kagoya Y, Ancruzowski M, Wang CH, Rahman MA, Saso K, Butler MO, Chiu PP, Julien JP, Hirano N.

J Immunol. 2017 Feb 1;198(3):1056-1065. doi: 10.4049/jimmunol.1601556. PMID: 28003379.

2016

Discrete TCR Binding Kinetics Control Invariant NKT Cell Selection and Central Priming.

Cruz Tleugabulova M, Escalante NK, Deng S, Fieve S, Ereño-Orbea J, Savage PB, Julien JP, Mallevaey T.

J Immunol. 2016 Nov 15;197(10):3959-3969. doi: 10.4049/jimmunol.1601382. PMID: 27798168.

Minimally mutated HIV-1 broadly neutralizing antibodies to guide reductionist vaccine design.

Jardine JG*, Sok D*, Julien J-P*, Briney B*, Sarkar A, Liang C-H, Scherer EA, Henry Dunand CJ, Adachi Y, Diwanji D, Hsueh J, Jones M, Kalyuzhniy O, Kubitz M, Spencer S, Pauthner M, Saye-Francisco KL, Sesterhenn F, Wilson PC, Galloway DM, Stanfield RL, Wilson IA, Burton DR, Schief WR.

PLoS Pathog. 2016 Aug 25;12(8):e1005815. doi:10.1371/journal.ppat.1005815. PMID: 27560183.

The structural basis of modified nucleosome recognition by 53BP1.

Wilson MD, Benlekbir S, Fradet-Turcotte A, Sherker A, Julien JP, McEwan A, Noordermeer SM, Sicheri F, Rubinstein JL, Durocher D.

Nature. 2016 Jul 27;536(7614):100-103. doi: 10.1038/nature18951. PMID: 27462807

Optimization of Glycoprotein Expression by Transient Transfection in HEK 293F/S suspension cells.

Akula I, Julien JP

Polyplus Transfections. 2016 May 25:1-6.

HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen.

Jardine JG, Kulp DW, Havenar-Daughton C, Sarkar A, Briney B, Sok D, Sesterhenn F, Ereño-Orbea J, Kalyuzhniy O, Deresa I, Hu X, Spencer S, Jones M, Georgeson E, Adachi Y, Kubitz M, deCamp AC, Julien JP, Wilson IA, Burton DR, Crotty S, Schief WR.

Science. 2016 Mar 25;351(6280):1458-63. doi: 10.1126/science.aad9195. PMID:27013733

EspP, an Extracellular Serine Protease from Enterohemorrhagic E. coli, Reduces Coagulation Factor Activities, Reduces Clot Strength, and Promotes Clot Lysis.

Kuo KH, Khan S, Rand ML, Mian HS, Brnjac E, Sandercock LE, Akula I, Julien JP, Pai EF, Chesney AE.

PLoS One. 2016 Mar 2;11(3):e0149830. doi: 10.1371/journal.pone.0149830. eCollection 2016. PMID:26934472

2015

Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes.

de Taeye SW, Ozorowski G, Torrents de la Peña A, Guttman M, Julien JP, van den Kerkhof TL, Burger JA, Pritchard LK, Pugach P, Yasmeen A, Crampton J, Hu J, Bontjer I, Torres JL, Arendt H, DeStefano J, Koff WC, Schuitemaker H, Eggink D, Berkhout B, Dean H, LaBranche C, Crotty S, Crispin M, Montefiori DC, Klasse PJ, Lee KK, Moore JP, Wilson IA, Ward AB, Sanders RW.

Cell. 2015 Dec 17;163(7):1702-15. doi: 10.1016/j.cell.2015.11.056. PMID:26687358

Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens.

Julien JP, Lee JH, Ozorowski G, Hua Y, Torrents de la Peña A, de Taeye SW, Nieusma T, Cupo A, Yasmeen A, Golabek M, Pugach P, Klasse PJ, Moore JP, Sanders RW, Ward AB, Wilson IA.

Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):11947-52. doi: 10.1073/pnas.1507793112. Epub 2015 Sep 8. PMID:26372963

Origins of a Vaccine-Induced, Human Anti-HIV-1 Antibody.

Julien JP.

EBioMedicine. 2015 Jul 16;2(7):632-3. doi: 10.1016/j.ebiom.2015.07.019. eCollection 2015 Jul. PMID:26288832

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.

Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-Ramírez M, Back JW, Koff WC, Julien JP, Rakasz EG, Seaman MS, Guttman M, Lee KK, Klasse PJ, LaBranche C, Schief WR, Wilson IA, Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP.

Science. 2015 Jul 10;349(6244):aac4223. doi: 10.1126/science.aac4223. Epub 2015 Jun 18. PMID:26089353

Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth.

Willis JR, Sapparapu G, Murrell S, Julien JP, Singh V, King HG, Xia Y, Pickens JA, LaBranche CC, Slaughter JC, Montefiori DC, Wilson IA, Meiler J, Crowe JE Jr.

J Clin Invest. 2015 Jun;125(6):2523-31. doi: 10.1172/JCI80693. Epub 2015 May 18. PMID:25985274

Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer.

Derking R, Ozorowski G, Sliepen K, Yasmeen A, Cupo A, Torres JL, Julien JP, Lee JH, van Montfort T, de Taeye SW, Connors M, Burton DR, Wilson IA, Klasse PJ, Ward AB, Moore JP, Sanders RW.

PLoS Pathog. 2015 Mar 25;11(3):e1004767. doi: 10.1371/journal.ppat.1004767. eCollection 2015 Mar. PMID:25807248

Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env.

Guttman M, Cupo A, Julien JP, Sanders RW, Wilson IA, Moore JP, Lee KK.

Nat Commun. 2015 Feb 5;6:6144. doi: 10.1038/ncomms7144. PMID:25652336

A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.

Pugach P, Ozorowski G, Cupo A, Ringe R, Yasmeen A, de Val N, Derking R, Kim HJ, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, Julien JP, Burton DR, Wilson IA, Sanders RW, Klasse PJ, Ward AB, Moore JP.

J Virol. 2015 Mar;89(6):3380-95. doi: 10.1128/JVI.03473-14. Epub 2015 Jan 14. PMID:25589637

2014

Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex.

Sok D, van Gils MJ, Pauthner M, Julien JP, Saye-Francisco KL, Hsueh J, Briney B, Lee JH, Le KM, Lee PS, Hua Y, Seaman MS, Moore JP, Ward AB, Wilson IA, Sanders RW, Burton DR.

Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17624-9. doi: 10.1073/pnas.1415789111. Epub 2014 Nov 24. PMID:25422458

Structural evolution of glycan recognition by a family of potent HIV antibodies.

Garces F, Sok D, Kong L, McBride R, Kim HJ, Saye-Francisco KF, Julien JP, Hua Y, Cupo A, Moore JP, Paulson JC, Ward AB, Burton DR, Wilson IA.

Cell. 2014 Sep 25;159(1):69-79. doi: 10.1016/j.cell.2014.09.009. PMID:25259921

Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy.

Murin CD, Julien JP, Sok D, Stanfield RL, Khayat R, Cupo A, Moore JP, Burton DR, Wilson IA, Ward AB.

J Virol. 2014 Sep 1;88(17):10177-88. doi: 10.1128/JVI.01229-14. Epub 2014 Jun 25. PMID:24965454

CD4-induced activation in a soluble HIV-1 Env trimer.

Guttman M, Garcia NK, Cupo A, Matsui T, Julien JP, Sanders RW, Wilson IA, Moore JP, Lee KK.

Structure. 2014 Jul 8;22(7):974-84. doi: 10.1016/j.str.2014.05.001. Epub 2014 Jun 12. PMID:24931470

Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.

Yasmeen A, Ringe R, Derking R, Cupo A, Julien JP, Burton DR, Ward AB, Wilson IA, Sanders RW, Moore JP, Klasse PJ.

Retrovirology. 2014 May 29;11:41. doi: 10.1186/1742-4690-11-41. PMID:24884783

Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV.

Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, Kulp DW, Julien JP, Menis S, Wickramasinghe L, Seaman MS, Schief WR, Wilson IA, Poignard P, Burton DR.

Sci Transl Med. 2014 May 14;6(236):236ra63. doi: 10.1126/scitranslmed.3008104. PMID:24828077

Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.

Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, de la Peña AT, Cupo A, Julien JP, van Gils M, Lee PS, Peng W, Paulson JC, Poignard P, Burton DR, Moore JP, Sanders RW, Wilson IA, Ward AB.

Immunity. 2014 May 15;40(5):669-80. doi: 10.1016/j.immuni.2014.04.008. Epub 2014 Apr 24. PMID:24768348

2013

The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies.

Sok D, Laserson U, Laserson J, Liu Y, Vigneault F, Julien JP, Briney B, Ramos A, Saye KF, Le K, Mahan A, Wang S, Kardar M, Yaari G, Walker LM, Simen BB, St John EP, Chan-Hui PY, Swiderek K, Kleinstein SH, Alter G, Seaman MS, Chakraborty AK, Koller D, Wilson IA, Church GM, Burton DR, Poignard P.

PLoS Pathog. 2013;9(11):e1003754. doi: 10.1371/journal.ppat.1003754. Epub 2013 Nov 21. Erratum in: PLoS Pathog. 2013 Dec;9(12). doi:10.1371/annotation/f1f8c791-61e9-45c6-a455-92c6dadf9f06. Kleinstein, Stephen H [corrected to Kleinstein, Steven H]. PMID:24278016

Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer.

Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, Sanders RW, Moore JP, Carragher B, Wilson IA, Ward AB.

Science. 2013 Dec 20;342(6165):1484-90. doi: 10.1126/science.1245627. Epub 2013 Oct 31. PMID:24179160

Crystal structure of a soluble cleaved HIV-1 envelope trimer.

Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA.

Science. 2013 Dec 20;342(6165):1477-83. doi: 10.1126/science.1245625. Epub 2013 Oct 31. PMID:24179159

Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation.

Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee JH, Cupo A, Korzun J, Derking R, van Montfort T, Julien JP, Wilson IA, Klasse PJ, Ward AB, Moore JP.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18256-61. doi: 10.1073/pnas.1314351110. Epub 2013 Oct 21. PMID:24145402

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Peña AT, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP.

PLoS Pathog. 2013 Sep;9(9):e1003618. doi: 10.1371/journal.ppat.1003618. Epub 2013 Sep 19. PMID:24068931

Ebolavirus VP35 coats the backbone of double-stranded RNA for interferon antagonism.

Bale S, Julien JP, Bornholdt ZA, Krois AS, Wilson IA, Saphire EO.

J Virol. 2013 Sep;87(18):10385-8. doi: 10.1128/JVI.01452-13. Epub 2013 Jul 3. PMID:23824825

Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein.

Klasse PJ, Depetris RS, Pejchal R, Julien JP, Khayat R, Lee JH, Marozsan AJ, Cupo A, Cocco N, Korzun J, Yasmeen A, Ward AB, Wilson IA, Sanders RW, Moore JP.

J Virol. 2013 Sep;87(17):9873-85. doi: 10.1128/JVI.01226-13. Epub 2013 Jul 3. PMID:23824824

Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers.

Khayat R, Lee JH, Julien JP, Cupo A, Klasse PJ, Sanders RW, Moore JP, Wilson IA, Ward AB.

J Virol. 2013 Sep;87(17):9865-72. doi: 10.1128/JVI.01222-13. Epub 2013 Jul 3. PMID:23824817

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120.

Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, Marozsan A, Cupo A, Klasse PJ, Hoffenberg S, Caulfield M, King CR, Hua Y, Le KM, Khayat R, Deller MC, Clayton T, Tien H, Feizi T, Sanders RW, Paulson JC, Moore JP, Stanfield RL, Burton DR, Ward AB, Wilson IA.

Nat Struct Mol Biol. 2013 Jul;20(7):796-803. doi: 10.1038/nsmb.2594. Epub 2013 May 26. PMID:23708606

Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans.

Julien JP, Sok D, Khayat R, Lee JH, Doores KJ, Walker LM, Ramos A, Diwanji DC, Pejchal R, Cupo A, Katpally U, Depetris RS, Stanfield RL, McBride R, Marozsan AJ, Paulson JC, Sanders RW, Moore JP, Burton DR, Poignard P, Ward AB, Wilson IA.

PLoS Pathog. 2013;9(5):e1003342. doi: 10.1371/journal.ppat.1003342. Epub 2013 May 2. PMID:23658524

Rational HIV immunogen design to target specific germline B cell receptors.

Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, Sok D, Huang PS, MacPherson S, Jones M, Nieusma T, Mathison J, Baker D, Ward AB, Burton DR, Stamatatos L, Nemazee D, Wilson IA, Schief WR.

Science. 2013 May 10;340(6133):711-6. doi: 10.1126/science.1234150. Epub 2013 Mar 28. PMID:23539181

Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Julien JP, Lee JH, Cupo A, Murin CD, Derking R, Hoffenberg S, Caulfield MJ, King CR, Marozsan AJ, Klasse PJ, Sanders RW, Moore JP, Wilson IA, Ward AB.

Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4351-6. doi: 10.1073/pnas.1217537110. Epub 2013 Feb 20. PMID:23426631

2012

Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.

Julien JP, Lee PS, Wilson IA.

Immunol Rev. 2012 Nov;250(1):180-98. doi: 10.1111/imr.12005. Review. PMID:23046130

Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism.

Bale S, Julien JP, Bornholdt ZA, Kimberlin CR, Halfmann P, Zandonatti MA, Kunert J, Kroon GJ, Kawaoka Y, MacRae IJ, Wilson IA, Saphire EO.

PLoS Pathog. 2012 Sep;8(9):e1002916. doi: 10.1371/journal.ppat.1002916. Epub 2012 Sep 13. PMID:23028316

Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers.

Depetris RS, Julien JP, Khayat R, Lee JH, Pejchal R, Katpally U, Cocco N, Kachare M, Massi E, David KB, Cupo A, Marozsan AJ, Olson WC, Ward AB, Wilson IA, Sanders RW, Moore JP.

J Biol Chem. 2012 Jul 13;287(29):24239-54. doi: 10.1074/jbc.M112.371898. Epub 2012 May 29. PMID:22645128

Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane.

Montero M, Gulzar N, Klaric KA, Donald JE, Lepik C, Wu S, Tsai S, Julien JP, Hessell AJ, Wang S, Lu S, Burton DR, Pai EF, Degrado WF, Scott JK.

J Virol. 2012 Mar;86(6):2930-41. doi: 10.1128/JVI.06349-11. Epub 2012 Jan 11. PMID:22238313

Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope.

Azoitei ML, Ban YE, Julien JP, Bryson S, Schroeter A, Kalyuzhniy O, Porter JR, Adachi Y, Baker D, Pai EF, Schief WR.

J Mol Biol. 2012 Jan 6;415(1):175-92. doi: 10.1016/j.jmb.2011.10.003. Epub 2011 Oct 31. PMID:22061265

2011

Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope.

Stanfield RL, Julien JP, Pejchal R, Gach JS, Zwick MB, Wilson IA.

J Mol Biol. 2011 Dec 2;414(3):460-76. doi: 10.1016/j.jmb.2011.10.014. Epub 2011 Oct 15. PMID:22033480

A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.

Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA.

Science. 2011 Nov 25;334(6059):1097-103. doi: 10.1126/science.1213256. Epub 2011 Oct 13. PMID:21998254

Broad neutralization coverage of HIV by multiple highly potent antibodies.

Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD; Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P.

Nature. 2011 Sep 22;477(7365):466-70. doi: 10.1038/nature10373. PMID:21849977

Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.

Maeso R, Huarte N, Julien JP, Kunert R, Pai EF, Nieva JL.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):863-76. doi: 10.1089/AID.2010.0265. Epub 2011 Jan 15. PMID:21142698